Filing Flows › Health Care › Cerus (CERS)
Cerus (CERS) earnings and revenue breakdown
Latest: Q3 2026 · 10-Q filed Nov 2, 2026 · Cerus (CERS) Q3 2026 earnings results →
Q3 2026 Revenue up 10% year over year to $57.7M · 1¢ of every $1 of revenue lost · operating margin 0.7%
Cerus made $57.7M in Q3 2026 (+10% Y/Y). Operating margin 0.7%, net loss $580K. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-Q filed Nov 2, 2026.
Drawing the Sankey…
Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF
What changed this quarter
Revenue was $57.7M in Q3 2026, up 10% year over year and roughly flat from the previous quarter.
Operating profit was $383K, a 0.7% margin (down 1.7 points year over year). Operating profit fell $853K even though revenue rose $5.0M versus a year earlier, so costs grew faster than sales. Total costs grew 11% against revenue growth of 10%. The fastest-growing cost line was Other operating costs (+24%). The quarter ended with a net loss of $580K, narrower than the previous quarter's $3.0M loss. Net interest and other expense of $897K was the main reason.
Operating cash flow was $3.0M (up 56% year over year). Non-cash charges added back $421K of depreciation and amortization and $6.1M of share-based compensation. Working capital and other items used $2.9M. Capital expenditures of $590K left free cash flow of $2.4M.
Quarterly history
| Quarter | Form | Filed | Revenue | Y/Y | Op. margin | Net earnings | Op. cash flow |
|---|---|---|---|---|---|---|---|
| Q3 2026 | 10-Q | Nov 2, 2026 | $57.7M | +10% | 0.7% | −$580K | $3.0M |
| Q2 2026 | 10-Q | Jul 30, 2026 | $57.4M | +10% | -3.2% | −$3.0M | −$2.7M |
| Q1 2026 | 10-Q | Apr 30, 2026 | $53.7M | +24% | -0.7% | −$1.6M | −$3.0M |
| Q2 2025 | 10-Q | Aug 5, 2025 | $52.4M | — | -6.5% | −$5.7M | −$2.4M |
| Q1 2025 | 10-Q | May 1, 2025 | $43.2M | — | -13.5% | −$7.7M | −$844K |
Charts
Interactive views
The same charts as the app — open one to draw it.
💵Where each $1 goesinteractive
Loading the interactive chart…
🌏Named in Asian annual reportsinteractive
Loading the interactive chart…
🔄Rotation against the market and its industry (RRG)interactive
Loading the interactive chart…
🔍Earnings qualityinteractive
Loading the interactive chart…
⚖️Fair value by methodinteractive
Loading the interactive chart…
🔭Outlook & guidanceinteractive
Loading the interactive chart…
📈Investments: gains and what it boughtinteractive
Loading the interactive chart…
🏭Its industry’s money flow (input-output)interactive
Loading the interactive chart…
About Cerus
Cerus Corporation is dedicated solely to safeguarding the world’s blood supply and aims to become the preeminent global blood products company. Headquartered in Concord, California, the company develops and supplies vital technologies and pathogen-protected blood components to blood centers, hospitals, and ultimately patients who rely on safe blood. The INTERCEPT Blood System for platelets and plasma is available globally and remains the only pathogen reduction system with both CE mark and FDA approval for these two blood components. In the U.S., the INTERCEPT Blood System for Cryoprecipitation is approved for the production of Pathogen Reduced Cryoprecipitated Fibrinogen Complex (commonly referred to as INTERCEPT Fibrinogen Complex), a therapeutic product for the treatment and control of bleeding, including massive hemorrhage, associated with fibrinogen deficiency.
In its own words, from its 8-K, filed Jul 30, 2026.
Cerus against its Surgical & Medical Instruments & Apparatus peers
The largest companies of the same SEC industry, each at its latest quarter. Revenue growth: +10% against the peers' median +5%. Operating margin: 0.7% against the peers' median 13.3%.
| Company | Quarter | Revenue | Y/Y | Op. margin |
|---|---|---|---|---|
| CERS Cerus | Q3 2026 | $57.7M | +10% | 0.7% |
| MDLN Medline | Q3 2026 | $7.9B | +10% | 6.4% |
| MMM 3M | Q3 2026 | $6.6B | +1% | 23.7% |
| SYK Stryker | Q3 2026 | $6.5B | +8% | 15.9% |
| BSX Boston Scientific | Q3 2026 | $5.1B | +1% | 16.1% |
| BDX Becton Dickinson | Q3 FY26 | $5.0B | +5% | 13.3% |
| BAX Baxter International | Q3 2026 | $3.0B | +5% | 7.6% |
| SOLV Solventum | Q3 2026 | $1.9B | -7% | 3.5% |
| RMD ResMed | Q1 FY27 | $1.4B | +6% | 32.0% |
Source: Cerus 10-Q on SEC EDGAR · CIK 1020214 · Surgical & Medical Instruments & Apparatus
Guidance and outlook
13F: who owns CERS and who is buying
More on CERS
History
Every quarter: Q3 2026 results · Q2 2026 results · Q1 2026 results · Q2 2025 results · Q1 2025 results